Accessibility Menu
Acrux logo

Acrux(ASX) ACR

Market CapA$5.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-98%
5 Year-92%
1 Year-29%
1 Month-9%
A$0.01
+0.00%
+0.00Today
Acrux last closing stock price
MetricPriceDate
Last closeAUD 0.012026-08-13
Acrux stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.09%AUD 0.012026-08-06
1 month-9.09%AUD 0.012026-07-14
3 month-9.09%AUD 0.012026-05-14
Year to date-33.33%AUD 0.022025-12-31
1 year-28.57%AUD 0.012025-08-13
3 year-78.26%AUD 0.052023-08-14
5 year-92%AUD 0.132021-08-13
Since inception-98.32%AUD 0.592004-09-29

Acrux Financials at a Glance

Market Cap

A$5.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.61M

Net Income (TTM)

-A$8.34M

EPS (TTM)

-A$0.01

P/E Ratio

-1.72

Dividend

A$0.00

Beta (Volatility)

-0.08 (Low)

Price

A$0.01

Volume

106,611

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.02

Estimated Earnings Date

Aug 21, 2026

ACR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acrux

Acrux Limited is a biotechnology company focused on developing and commercializing generic and topically applied pharmaceutical products. The company operates globally, providing a range of testosterone therapies and estradiol sprays for various medical conditions.

Products and Services
  • Testosterone therapies including oral tablets, patches, and gels
  • Estradiol sprays marketed as Evamist and Lenzetto for menopause management
  • Innovative delivery systems for hormone replacement therapies
Growth Outlook
  • Recent quarterly revenue increased to AUD 1.74 million, showing positive momentum
  • Gross profit margin improved to 87.24% in the latest quarter
  • Expansion into international markets enhances growth potential
Financial Highlights
  • Trailing twelve months revenue of AUD 6.5 million, indicating steady demand
  • Net income of AUD 165,000 reported in the latest quarter, a significant turnaround
  • Current ratio of 1.35 suggests strong short-term financial health
Acrux Limited has established itself as a key player in the biotechnology sector, particularly in hormone replacement therapies. The company's diverse product offerings cater to both men and women, addressing critical health needs. Recent financial performance indicates a positive trend, with increasing revenues and improving profit margins. The company's strategic focus on international expansion positions it well for future growth, making it an intriguing option for potential investors interested in the biotechnology field.
AI Generated • Aug 6, 2026

Industry

Pharmaceuticals

CEO

John Warmbrunn

Headquarters

West Melbourne, VIC 3003, AU

ACR Financials

Key Financial Metrics (TTM)

Gross Margin

56.94%

Operating Margin

-185.41%

Net Income Margin

-83.81%

Return on Equity

-211.88%

Return on Capital

-192.61%

Return on Assets

-49.76%

Earnings Yield

-58.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$5.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

589.68M

Volume

106.61K

Avg. Volume

1.74M

Financials (TTM)

Gross Profit

-A$218.00K

Operating Income

-A$15.19M

EBITDA

-A$13.62M

Operating Cash Flow

-A$6.71M

Capital Expenditure

-A$125.00K

Free Cash Flow

-A$6.84M

Cash & ST Invst.

A$946.00K

Total Debt

A$3.64M

Acrux Performance Analysis

Acrux annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 1,719,000N/A
20232023-06-30AUD 8,429,000390.3%
20242024-06-30AUD 5,091,000-39.6%
20252025-06-30AUD 1,190,000-76.6%
Acrux sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-84.5%
Q22024-12-31-82.4%
Q42025-06-30791.7%
Q22025-12-3162.6%
Acrux annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.03N/A
20232023-06-30AUD -0.00-92.2%
20242024-06-30AUD -0.02640.7%
20252025-06-30AUD -0.02-15.5%
Acrux sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3021.4%
Q22024-12-31-29.5%
Q42025-06-3045.6%
Q22025-12-31106.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$1.74M

-60.5%

Gross Profit

A$1.52M

+166.7%

Gross Margin

87.24%

N/A

Market Cap

A$5.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$137.13K

N/A

Employees

43

N/A

Net Income

A$165.00K

+105.1%

EBITDA

-A$1.07M

+73.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$946.00K

-79.3%

Total Debt

A$3.64M

+61.1%

Accounts Receivable

A$1.63M

-58.6%

Inventory

A$0.00

N/A

Long Term Debt

A$2.88M

+47.6%

Short Term Debt

A$756.00K

+23.9%

Return on Assets

-49.76%

N/A

Return on Invested Capital

-1.94%

N/A

Free Cash Flow

A$1.74M

+210.6%

Operating Cash Flow

A$1.74M

+222.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IBX.AXImagion Biosystems Limited
A$0.01-15.38%
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%
HIQ.AXHITIQ Limited
A$0.01+0.00%
ZLD.AXZelira Therapeutics Limited
A$0.50+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About ACR

What is the current price of Acrux?

Acrux is trading at A$0.01 per share.

What is the 52-week range for Acrux?

Over the past 52 weeks, Acrux has traded between A$0.01 and A$0.02.

How much debt does Acrux have?

As of the most recent reporting period, Acrux reported total debt of A$3.64M.

How much cash does Acrux have on hand?

Acrux reported A$863.00K in cash and cash equivalents in its most recent financial results.

What is Acrux’s dividend yield?

Acrux does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.